Variable | N (%) or Mean ± SD |
---|---|
Age, years (mean ± SD) | 40 ± 10.9 |
Gender (male) | 89 (23.3%) |
Marital status | |
 Single | 154 (40.3%) |
 Married | 228 (59.7%) |
level of education | |
 Undergraduate | 27(7.1%) |
 Diploma | 102(26.7%) |
 Associate degree | 15(3.9%) |
 Bachelor | 152(39.8%) |
 Master | 64(16.8%) |
 Professional doctoral degree | 22(5.8%) |
Job | |
 Unemployed | 28 (7.3%) |
 Freelance | 134 (35.1%) |
 Government | 16 (4.2%) |
 Housewife | 168 (44%) |
 Student | 13 (3.4%) |
 Retired | 23 (6%) |
Income | |
 No income | 214 (56%) |
 1–5 million toman/month | 81 (21.2%) |
 5–10 million toman/month | 62 (16.2%) |
  > 10 million toman/month | 25 (6.5%) |
Physical activity | |
 Low | 246 (64.4%) |
 Moderate | 88 (23%) |
 High | 48 (12.6%) |
Comorbidity | |
 Heart disease | 6 (1.6%) |
 Diabetes | 7 (1.8%) |
 Hypertension | 15 (3.9%) |
 Hypothyroid | 20 (5.2%) |
Hyperthyroid | 2 (0.5%) |
 Cancer | 6 (1.6%) |
 Stroke | 1 (0.3%) |
 Depression | 19 (5%) |
Duration of MS* disease, months | 111 ± 78 |
MS subtype | |
 RRMS* | 354 (92.7%) |
 PMS* | 28 (7.3%) |
Mode of MS medication administration | |
 Oral | 254 (66.5%) |
 Injection | 128 (33.5%) |
Anti-depressant drugs | |
 Tricyclic antidepressants | 1% |
 Selective serotonin reuptake inhibitors | 1.7% |
 Serotonin-norepinephrine reuptake inhibitor | 1.5% |
 Atypical | 0.5% |
Antianxiety drugs | |
 anticonvulsant | 2.4% |
 benzodiazepines | 1.3% |
 Nonbenzodiazepines | 0.5% |
Supplements | |
 Yes | 305 (79.8%) |
 No | 77 (20.2%) |
 Number of daily supplements used | 1 ± 1.3 |
 Supplement used duration, months | 79.2 ± 105 |